XBP1 as a novel molecular target to attenuate drug resistance in hepatocellular carcinoma

IF 4.6 2区医学 Q1 PHARMACOLOGY & PHARMACY

Expert Opinion on Therapeutic Targets Pub Date : 2023-12-11 DOI:10.1080/14728222.2023.2293746

Zahra Hendi, Pedram Asadi Sarabi, David Hay, Massoud Vosough

引用次数: 0

Abstract

Despite improvements in clinical management of hepatocellular carcinoma (HCC), prognosis remains poor with a 5-year survival rate less than 40%. Drug resistance in HCC makes it challenging to treat...

查看原文本刊更多论文

XBP1 作为减轻肝细胞癌耐药性的新型分子靶点

尽管肝细胞癌（HCC）的临床治疗有所改善，但预后仍然很差，5年生存率不到40%。肝细胞癌的耐药性使治疗具有挑战性...

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Expert Opinion on Therapeutic Targets 医学-药学

CiteScore

8.90

自引率

1.70%

发文量

审稿时长

3 months

期刊介绍： The journal evaluates molecules, signalling pathways, receptors and other therapeutic targets and their potential as candidates for drug development. Articles in this journal focus on the molecular level and early preclinical studies. Articles should not include clinical information including specific drugs and clinical trials. The Editors welcome: Reviews covering novel disease targets at the molecular level and information on early preclinical studies and their implications for future drug development. Articles should not include clinical information including specific drugs and clinical trials. Original research papers reporting results of target selection and validation studies and basic mechanism of action studies for investigative and marketed drugs. The audience consists of scientists, managers and decision makers in the pharmaceutical industry, academic researchers working in the field of molecular medicine and others closely involved in R&D.